Determination of antimicrobial drug Ro 12-6995 (a 2,4-diamino-5-benzylpyrimidine) in blood plasma by high-performance liquid chromatography

Summary A HPLC procedure for the determination of Ro 12-6995, a new antimicrobial drug, in blood plasma is described. Adsorption liquid chromatography with LiChrosorb Si 60 as stationary phase with fluorescence detection was used to quantify the drug, which is extracted from plasma with n-butyl acetate. Due to the high fluorescence of Ro 12-6995, the plasma extracts can be injected directly onto the column and no evaporation step in the sample preparation is necessary. The assay is rapid, accurate and sensitive, and easily applicable to the determination of plasma series.     

Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5- tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography.

A fast and reliable method has been established for the determination of the dopamine D-1 receptor antagonist (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1 H-3- benzazepin-7-ol (NNC 01-0687) in plasma. A combination of reversed-phase extraction on C18 columns and straight-phase high-performance liquid chromatographic analysis with ultraviolet detection at 287 nm resulted in very clean chromatograms. The limit of quantitation was about 1 ng/ml of plasma. Validation of the method showed good selectivity, linearity, recovery, accuracy and precision. Several modifications of the method were possible with little or no influence on the assay.     

Rapid determination of the benzodiazepine antagonist flumazenil, Ro 15-1788, by high performance liquid chromatography

A sensitive (2 ng/mL) and specific method for the determination of the benzodiazepine antagonist Ro 15-1788 or flumazenil is described. Following a simple extraction, the compound is analyzed by reversed phase high performance liquid chromatography (HPLC) and detection at 245 nm. The method was applied to plasma specimens collected from patients receiving a single dose of this drug.     

Chemoenzymatic synthesis of Ro 25-8210 and Ro 25-6630

Here we report the chemoenzymatic synthesis of Ro 25-8210 (1) and Ro 25-6630 (2) by using microbial reduction of a-chloromethyl ketone 4 mediated with baker's yeast and Geotrichum sp. to afford the optically active (R) and (S)-α-chlorohydrin 8 respectively as the key step.     

Determination of 7-iodo-1,3-dihydro-1-methyl-5(2'-fluorophenyl)-2h-1,4-benzodiazepin-2-one (Ro 7-9957) and its major biotransformation products in blood and urine by electron capture-gas-liquid chromatography.

A sensitive and specific electron capture-gas chromatographic assay was developed for the determination of 7-iodo-1,3-dihydro-1-methyl-5(2'-fluorophenyl)-2H-1,4-benzodiazepin-2-one (I) and its major metabolites in blood and urine. The overall recovery of I and its N-desmethyl metabolite (II) from blood is apparently quantitative. The recovery of the major urinary metabolite, the N-desmethyl-3-hydroxy analog (IV), and the minor metabolites, the N-desmethyl analog (II) and the N-methyl-3-hydroxy analog (III) added to urine as authentic reference standards ranged from 80 to 85%. The sensitivity limits of detection are of the order of 2-3 ng of I and 4-5 ng of II per ml of blood or urine. The method was applied to the determination of blood levels and the urinary excretion pattern in a dog following oral and intravenous administration of a 1-mg/kg dose (total 13 mg), and in man following the intravenous administration of single 5- and 10-mg doses. The N-desmethyl metabolite II was more predominant in dog blood than was the orally or intravenously administered I, but II was barely measurable in human blood.     

Determination of Ro 14-1761, a new third-generation cephalosporin, in the plasma and milk of cattle by column switching high-performance liquid chromatography

A sensitive and specific high-performance liquid chromatographic procedure was developed for the determination of the third-generation cephalosporin Ro 14-1761 in cow plasma and milk. The molecular structure of the new antimicrobial was very close to that of ceftriaxone, but the high-performance liquid chromatographic methods available for the latter could not be used as Ro 14-1761 adsorbed and/or degraded during the chromatographic process. Furthermore, the high-performance liquid chromatographic technique derived for ceftriaxone was not sensitive enough for our purposes. In the new assay, the plasma (milk) protein was precipitated with acetonitrile after dilution of the sample with water. For low concentrations (less than or equal to 10 micrograms/ml), the supernatant obtained after centrifugation was concentrated by extracting acetonitrile with methylene chloride. Quantification was performed by column switching high-performance liquid chromatography with UV detection (274 nm) using ion-pair reversed-phase chromatography. Ethylenediaminotetraacetic sodium salt had to be added to the mobile phase (1.2 mM) to prevent adsorption and/or degradation of the cephalosporin on the analytical column. The selectivity of the chromatographic separation was enhanced by heating the column to ca. 50 degrees C. The drug recovery was better than 85%. The limit for quantitative determination in both milk and plasma was 0.1 microgram of Ro 14-1761 per millilitre with an accuracy of 1% (coefficient of variation 10%). The overall accuracy and precision were 1-10% in the 0.1-100 micrograms/ml concentration range.     

1-(5-萘酚-7-磺酸)-3-[4-(苯基偶氮)苯基]-三氮烯的合成及与阳离子表面活性剂的显色反应

报道了1-（5-萘酚-7-磺酸）-3-[4-（苯基偶氮）苯基]-三氮烯（NASAPAPT）的合成，研究了该试剂与阳离子表面活性剂溴化十二烷基二甲基苄铵（DDMBAB），溴化十六烷基三甲铵（CTMAB）、溴化十六烷基吡啶（CPB）、溴化十四烷基吡啶（TPB）显色反应的条件。测定了显色反应的灵敏度，符合比尔定律的范围。建立了光度法测定微量阳离子表面活性剂的新方法。     

Determination of the N-methyl- -aspartate receptor NR2B subunit blocker Ro 63-1908 in rat, cynomolgus monkey and human plasma by high-performance liquid chromatography with column switching and fluorescence detection

A HPLC method with automated column switching was developed and validated for the determination of Ro 63-1908 in rat and cynomolgus monkey plasma. Human plasma was used for calibration and was also included in the validation process. Ro 63-1908 belongs to a class of neuroprotective N-methyl- -aspartate (NMDA) receptor blockers which were in development for the treatment of stroke and traumatic brain injury. The method involves deproteinisation of plasma samples with ethanol and direct injection of the supernatant (1.4 ml) into the HPLC column-switching system. To prevent a breakthrough of the analyte and the internal standard on the precolumn (Purospher RP-18, 75×4 mm) due to the high ethanol content, the injection solution was diluted, on-line, using an additional pump and a T-piece. 1% ammonium acetate–ethanol (100:2, v/v) was used as mobile phase for injection, as well as for on-line dilution, resulting in pre-concentration of the analyte and the internal standard on the precolumn. As Purospher RP-18 is a non-endcapped stationary phase with a special selectivity for amines, the analyte and the internal standard could then be selectively eluted with 30% acetonitrile (without any buffer in the mobile phase) and transferred to the analytical column [consisting of two coupled columns (125+250×4 mm) packed with Superspher 60 RP-select B], where they were separated by gradient elution and detected by fluorescence detection. Compared to the use of a 125 mm long precolumn and dilution of the supernatant with ammonium acetate prior to injection, the 75 mm precolumn and the on-line dilution procedure allowed about one third shorter run times (21 min) and, therefore, a higher sample throughput. The limit of quantification was 1 ng/ml using 0.4 ml plasma. The method was applied to more than 670 plasma samples from pharmacokinetic and toxicokinetic studies and is also suitable for other matrices and NMDA receptor blockers.     

Determination of Arotinoid Ro 15–0778 and its Metabolite in Plasma by HPLC

Abstract

A method is described for the quantitative analysis in plasma of Ro 15–0778, an arotinoid, (E)-1, 2, 3, 4-tetrahydro-1, 1, 4, 4-tetramethyl-6-(1-methyl-2-phenylethenyl) naphthalene and its metabolite Ro 14–6113, (E)-4- 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2 methylethenyl) phenol. Following a simple extraction, the compounds are determined by reversed-phase high-performance liquid chromatography (HPLC) and detection at 300 nm. The experimental error is below 12% in the concentration range 6–4350 ng/ml. The detection limit is about 2 ng/ml. This method was applied to plasma specimens collected from patients receiving single or multiple dose administration of this compound.     

Determination of the cephalosporin Ro 13-99041 in plasma,urine, and bile by means of ion-pair reversed phase chromatography

An HPLC method has been developed for the determination of the cephalosporin antibiotic Ro 13-9904 in plasma, urine, and bile of dogs and of human volunteers using the technique of ion-pair chromatography with a LiChrosorb RP-18 column. The three mobile phases employed contained tetrapentyl-, tetraoctyl- and hexadecyltrimethyl-ammonium bromide, respectively, as lipophilic counterions. The chromatographic conditions chosen allowed simple and rapid sample preparation. Plasma was deproteinized with ethanol and the supernatant was directly injected onto the column; urine and bile were diluted with mobile phase and injected without any purification. The detection limit for the cephalosporin was about 0.5 μg/ml for plasma samples and approximately 5 μg/ml for bile and urine.     

Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection.

A sensitive and specific high-performance liquid chromatographic method has been developed to measure the catechol-O-methyl-transferase (COMT) inhibitor 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone (Ro 40-7592) in human plasma. The compound and the internal standard were extracted from plasma at pH 2 with n-butyl chloride-ethyl acetate (95:5, v/v). The extract was chromatographed on a reversed-phase column (Hypersil ODS, 5 microns) using a mixture of phosphate buffer (0.05 M, pH 2), methanol and tetrahydrofuran (45:55:5, v/v/v) as the mobile phase. Long-retained components were removed from the system by means of a simple column-switching system. Quantification of the catechol-O-methyltransferase inhibitor was performed by means of coulometric detection (0.1 V). The limit of quantification was about 1 ng/ml, using a 1-ml specimen of plasma. The recovery from human plasma was greater than 88%. The mean inter-assay precision was 5.3% in the range 2.5-1000 ng/ml. Linearity of the standard curve was obtained in the concentration range 2.5-500 ng/ml. The catechol-O-methyltransferase inhibitor was stable in human plasma when stored for six months at -20 degrees C and for 24 h at room temperature. The practicability of the new method was demonstrated by the analysis of more than 400 plasma samples from a tolerance study performed in human volunteers.     

Determination of the imidazo quinazoline derivative Ro 13-6438 in biological fluids by high-performance liquid chromatography

A high-performance liquid chromatographic assay has been developed for the imidazo quinazoline derivative Ro 13-6438 [D-(-)-6-chloro-1,5-dihydro-3-methylimidazo(2,1-b)-quinazolin++ +-2(3H)-one], which is under clinical investigation as a cardioactive drug. The drug is extracted from biological fluids into 1-chlorobutane--1-hexanol (90:10) and back-extracted into perchloric acid. This extract is chromatographed directly, using a reversed-phase high-performance liquid chromatographic system with ultraviolet detection at 254 nm. The detection limit in plasma is about 1 ng ml-1, using a 1-ml sample. The assay is rapid, accurate and sufficiently sensitive for the study of the single-dose kinetics of Ro 13-6438 in man following a 7.5-mg intravenous dose. No instability of the unchanged substance was observed in plasma during storage for one day at room temperature and for five months at --20 degrees C.     

Preparation and evaluation of liposomes encapsulating synthetic MMP inhibitor (Ro 28-2653)—cyclodextrin complexes

In this study, preparation and evaluation of liposomes, intended for intravenous administration, encapsulating synthetic MMP inhibitor (Ro 28-2653) – cyclodextrin complexes were realized. An increase in Ro solubility, via formation of binary (Ro/HPβCD) or ternary (Ro/HPβCD/L-lysine) complexes, permitted a similar increase in encapsulation efficiency of liposomes (Table 1). Moreover, Ro release kinetics depend on the encapsulation efficiency.     

Determination of the N-methyl-D-aspartate receptor NR2B subunit blocker Ro 63-1908 in rat, cynomolgus monkey and human plasma by high-performance liquid chromatography with column switching and fluorescence detection

A HPLC method with automated column switching was developed and validated for the determination of Ro 63-1908 in rat and cynomolgus monkey plasma. Human plasma was used for calibration and was also included in the validation process. Ro 63-1908 belongs to a class of neuroprotective N-methyl-D-aspartate (NMDA) receptor blockers which were in development for the treatment of stroke and traumatic brain injury. The method involves deproteinisation of plasma samples with ethanol and direct injection of the supernatant (1.4 ml) into the HPLC column-switching system. To prevent a breakthrough of the analyte and the internal standard on the precolumn (Purospher RP-18, 75x4 mm) due to the high ethanol content, the injection solution was diluted, on-line, using an additional pump and a T-piece. 1% ammonium acetate-ethanol (100:2, v/v) was used as mobile phase for injection, as well as for on-line dilution, resulting in pre-concentration of the analyte and the internal standard on the precolumn. As Purospher RP-18 is a non-endcapped stationary phase with a special selectivity for amines, the analyte and the internal standard could then be selectively eluted with 30% acetonitrile (without any buffer in the mobile phase) and transferred to the analytical column [consisting of two coupled columns (125+250x4 mm) packed with Superspher 60 RP-select B], where they were separated by gradient elution and detected by fluorescence detection. Compared to the use of a 125 mm long precolumn and dilution of the supernatant with ammonium acetate prior to injection, the 75 mm precolumn and the on-line dilution procedure allowed about one third shorter run times (21 min) and, therefore, a higher sample throughput. The limit of quantification was 1 ng/ml using 0.4 ml plasma. The method was applied to more than 670 plasma samples from pharmacokinetic and toxicokinetic studies and is also suitable for other matrices and NMDA receptor blockers.     

Sensitive fluorometric detection of prostaglandins by high performance liquid chromatography after precolumn labelling with 4-(N,N-dimethylaminosulphonyl)-7-(1-piperazinyl)-2,1,3-benzoxadiazole (DBD-PZ).

A highly sensitive and simple method for the determination of prostaglandins (PGs) by HPLC with fluorescence detection is described. PGs are converted to the corresponding fluorescence derivatives by the reaction with 4-(N,N-dimethylaminosulphonyl)-7-(1-piperazinyl)-2,1,3-benzoxadiaz ole (DBD-PZ) in the presence of 2,2'-dipyridyl disulphide and triphenyl phosphine in acetonitrile. The reaction is completed at room temperature after 30 min. The DBD derivatives of nine PGs are separated within a single 45 min chromatographic run on a reversed phase ODS column with a linear gradient elution using water and acetonitrile. The detection limits (signal-to-noise ratio of 3) calculated from the standard mixture of PGs (6-keto-F1 alpha, F1 alpha, F2 alpha, E1, E2, D2, limaprost, A1 and B1) are in the range 1.7-5.0 fmol. The applicability of the proposed procedure is evaluated to the detection of PGs added to rat plasma.     

Extraction and spectrophotometric determination of Pd(II) with 3,4,4a,5-tetrahydro-3,3,4a-trimethyl-7-(substituted)-pyrimido(1,6-a)-benzimidazole-1-thiol (PBT)

A method for the extraction-spectrophotometric determination of palladium with 3,4,4a,5-tetrahydro-3,3,4a-trimethyl-7-(substituted)-pyrimido(1,6-a)benzimidazole-1-thiol (PBT) is described. PBT-Pd(II) complex is extracted from an acidic aqueous solution (0.01-0.5M HClO(4)) into a chloroform layer. The absorbance is measured at 438 nm and the molar absorptivity found to be 1.033 x 10(4)M(-1) cm(-1). The complex system conforms to Beer's law over the range 1.9-28.5 mug/ml palladium(II). The effects of pH (2-6), HClO(4) concentration, PBT concentration and shaking time were studied. The ratio of metal ion to ligand molecules in the coloured complex was found to be 1:4. The tolerance limit for many metals have been determined. Finally, the method has been applied successfully to the determination of palladium in synthetic mixtures and in the standard palladium carbon powder (palladium catalyst).     

Spectrophotometric determination of thorium in food using 2-(2,5-disulfonic-4-methoxyphenylazo)-7-(2-hydroxyl-5-carboxylphenylazo)-1,8-dihydroxynaphthalene-3,6-disulfonic acid

A new highly sensitive and selective chromogenic reagent, 2-(2,5-disulfonic-4-methoxyphenylazo)-7-(2-hydroxyl-5-carboxylphenylazo)-1,8-dihydroxynaphthalene-3,6-disulfonic acid (1), was synthesized and applied to the spectrophotometric determination of trace thorium. In 5 mL of a 6 M perchloric acid medium, which greatly increases the selectivity, thorium reacts with 1 to form a 1: 2 green complex, having a sensitive absorption peak at 670 nm. Under optimal conditions, Beer’s law is obeyed over the range from 0 to 0.8 μg/mL Th(IV) and the apparent molar absorptivity is 2.09 × 10⁵ L/mol cm. It is found that, uranium(VI), Ti(IV), heavy rare earths, and most of other common metal ions do not interfere. The method has been tested on the determination of thorium in food samples with satisfactory results. The text was submitted by the authors in English.     

Colour reaction of platinum(II) with 5-(4-nitrophenylazo)-8-(p-toluenesulphonamido)-quinoline and its analytical applications

A simple, rapid and sensitive spectrophotometric method has been developed for the determination of platinum. 5-(4-Nitrophenylazo)-8-(p-toluenesulphonamido)quinoline (NPTSQ) reacts with platinum(II) almost instantaneously in alkaline solution to form a violet-red 1:2 complex with an absorption maximum at 640 nm. Beer's law is obeyed over the concentration range 0-1 mug/ml platinum. The molar absorptivity is 1.37 x 10(5) 1.mole(-1).cm(-1). The method has been used for the determination of microamounts of platinum in catalysts and anode slime.     

LC-MS/MS determination of 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4-pyridinecarboxylic acid (ABT-279) in dog plasma with high-throughput protein precipitation sample preparation

As an effective DPP-IV inhibitor, 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4-pyridinecarboxylic acid (ABT-279), is an investigational drug candidate under development at Abbott Laboratories for potential treatment of type 2 diabetes. In order to support the development of ABT-279, multiple analytical methods for an accurate, precise and selective concentration determination of ABT-279 in different matrices were developed and validated in accordance with the US Food and Drug Administration Guidance on Bioanalytical Method Validation. The analytical method for ABT-279 in dog plasma was validated in parallel to other validations for ABT-279 determination in different matrices. In order to shorten the sample preparation time and increase method precision, an automated multi-channel liquid handler was used to perform high-throughput protein precipitation and all other liquid transfers. The separation was performed through a Waters YMC ODS-AQ column (2.0 x 150 mm, 5 microm, 120 A) with a mobile phase of 20 mm ammonium acetate in 20% acetonitrile at a flow rate of 0.3 mL/min. Data collection started at 2.2 min and continued for 2.0 min. The validated linear dynamic range in dog plasma was between 3.05 and 2033.64 ng/mL using a 50 microL sample volume. The achieved r(2) coefficient of determination from three consecutive runs was between 0.998625 and 0.999085. The mean bias was between -4.1 and 4.3% for all calibration standards including lower limit of quantitation. The mean bias was between -8.0 and 0.4% for the quality control samples. The precision, expressed as a coefficient of variation (CV), was < or =4.1% for all levels of quality control samples. The validation results demonstrated that the high-throughput method was accurate, precise and selective for the determination of ABT-279 in dog plasma. The validated method was also employed to support two toxicology studies. The passing rate was 100% for all 49 runs from one validation study and two toxicology studies.     

LC Determination of Thiols Derivatized with 4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole after SPE

Solid-phase extraction (SPE) coupled with high-performance liquid chromatography?Cfluorescence detection (LC?CFL) was developed for the determination of three thiol compounds including glutathione, cysteine and acetylcysteine. 4-(Aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole was used for derivatization of thiols. Factors affecting derivatization and extraction efficiency were optimized. Sample solution (2?mL) was extracted on a SPE column for 2?min and then eluted with 400???L methanol. The analytes were injected onto the LC system for separation on a C₁₈ column, and eluted with methanol?Cacetate buffer. The analytes were detected by fluorescence at an emission wavelength of 515?nm with excitation at 385?nm. The linearity of the method was in the range of 0.1?C60???M, with correlation coefficients ranging from 0.9979 to 0.9990. The detection limits of the method were in the range of 5?C20?nM. The proposed method was applied to the analysis of human plasma samples with recoveries of 86?C112.9%.